In contrast, the combination of C‐C motif chemokine ligand 2 (CCL2) and interferon gamma (IFN‐g) can drive an anti‐tumour phenotype in PDAC myeloid cells, and this is particularly important in the presence of CD40 agonist treatment.95 This evidence concerns the gene IFNG and neoplasm.